📚 New to this topic? Read our full guide: Indian Economy Explained.
Biopharma Shakti Scheme To Roll Out In 3 Months With Focus On Faster Drug Approvals
India’s big new Biopharma Shakti scheme is set to roll out in about three months. That is the word from Manoj Joshi, Secretary at the Department of Pharmaceuticals. The scheme is meant to make India a global leader in advanced medicines. A key promise is faster drug approvals and strong support for startups. This could be a game-changer for India’s medicine industry.
The plan is huge. The government has set aside ₹10,000 crore over five years for it. The goal is to build a world-class home-grown ecosystem for biologics and biosimilars. We will explain those terms below in plain words.
What Is Biopharma Shakti In Simple Words?
Biopharma Shakti is a government scheme to grow India’s advanced medicine sector. It focuses on biologics and biosimilars. A biologic is a medicine made from living cells, not chemicals, used to treat illnesses like cancer and diabetes. A biosimilar is a cheaper, near-copy of a biologic made after the original’s patent ends. These medicines are costly and complex to make. India wants to make more of them at home.
Manoj Joshi is the Secretary of the Department of Pharmaceuticals, which sits under the Ministry of Chemicals and Fertilizers. He said the scheme will roll out in roughly three months. He stressed the need to boost innovation, speed up drug discovery, support new biopharma firms, and make supply chains stronger.
Faster Drug Approvals Are A Big Promise
One of the biggest goals is to speed up how fast new medicines get approved. Right now, getting a new drug cleared in India can be slow. The scheme plans to strengthen the CDSCO, India’s main drug regulator (the body that checks if a medicine is safe before it can be sold).
To do this, the government will create a dedicated Scientific Review Cadre, a special team of experts to review drug applications. The aim is faster, globally trusted approvals. That helps Indian firms launch medicines quicker and sell them abroad.
Big Money For Startups And Small Firms
The scheme gives real cash support to startups and small companies. For smaller projects worth up to ₹9 crore, a startup or MSME (micro, small and medium enterprise) can get up to ₹5 crore in help. For bigger projects worth up to ₹285 crore, the maximum help is ₹100 crore. This lowers the heavy upfront cost of building biologic factories.
| Key fact | Figure (as reported) |
|---|---|
| Total scheme outlay | ₹10,000 crore |
| Scheme duration | 5 years |
| Expected rollout | about 3 months |
| Help for projects up to ₹9 crore | up to ₹5 crore |
| Help for projects up to ₹285 crore | up to ₹100 crore |
| Long-term goal | 100 biologics by 2047 |
The Long-Term Vision
The scheme has a far-reaching aim. India wants to launch 100 biologics by 2047, the year that marks 100 years of independence. Before the rollout, the Department of Pharmaceuticals held wide talks with government bodies, industry leaders, startups, and contract research and manufacturing firms. The scheme will go live after all approvals, including from the Expenditure Finance Committee and the Cabinet.
FAQ
When will Biopharma Shakti roll out?
Pharma Secretary Manoj Joshi said it should roll out in about three months, after final approvals from the Expenditure Finance Committee and the Cabinet.
How much money is in the scheme?
The scheme has a total outlay of ₹10,000 crore spread over five years to build India’s biologics and biosimilars ecosystem.
How will it help startups?
Startups and MSMEs can get up to ₹5 crore for projects up to ₹9 crore, and up to ₹100 crore for projects up to ₹285 crore, cutting the high cost of entry.
Why It Matters (Especially For India And Founders)
India is already known as the “pharmacy of the world” for cheap generic medicines. But biologics are the future, and they are costly and hard to make. This scheme helps India catch up. For founders in biotech, the cash support and faster approvals lower two of the biggest hurdles: money and time.
This fits India’s wider push to lead in deep-tech and high-value industries, much like the country’s broader AI and innovation drive. More home-made biologics also mean cheaper life-saving drugs for Indian patients and a stronger health supply chain.
The bottom line: Biopharma Shakti is a ₹10,000 crore bet on India’s medicine future. With faster approvals, big startup support, and a goal of 100 biologics by 2047, the three-month rollout could reshape India’s pharma map.
Sources: Financial Express and Press Information Bureau.
